IRB #

IRB00005364

Title

Phase I/II randomized trial of LBH589 (Panobinostat) at two dose levels combined with bicalutamide (Casodex®) in men with castration-resistant prostate cancer

Principal Investigator

Joshi Alumkal

Study Purpose

To find out how effective the study drug LBH589 (Panobinostat) and bicalutamide are against prostate cancer, based on time to prostate-specific antigen (PSA) progression, and/or progression by imaging (CT scan, bone scan) and, to find out the side effects of LBH589.

Medical Condition(s)

Prostate

Eligibility Criteria

- Subjects must have prostate cancer which has not responded to initial hormone treatment and is progressing by PSA or scans.
- Subjects medical history will be reviewed in detail for study eligibility.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

New York University School of Medicine

Recruitment End

Compensation Provided

No